Infectious Disease
RSSArticles
-
Preventing Respiratory Syncytial Virus Illness in Infants
Prevention of respiratory syncytial virus (RSV) illness by using a monoclonal antibody, nirsevimab, in young infants entering the winter RSV season was recommended in 2023. Subsequently, effectiveness was evaluated in children in the northeastern United States. Nirsevimab was 68% effective in preventing RSV-associated need for medical care and 81% effective in preventing hospitalization for RSV-related illness.
-
Antibiotics for Asymptomatic Bacteriuria: Using Urinalysis to Improve Stewardship
A cohort study found that in patients receiving antibiotics for a urinary tract infection, a urinalysis with pyuria and/or nitrituria identified 40% more cases of unnecessary antibiotic use compared to asymptomatic bacteriuria.
-
Aztreonam and Avibactam for Injection (Emblaveo)
The U.S. Food and Drug Administration has approved a new combination antibiotic for the treatment of complicated intra-abdominal infections where there are limited or no alternative options.
-
Death Due to the ‘No Name’ Virus in Santa Fe
On Feb. 26, 2025, it was announced that the bodies of actor Gene Hackman and his wife and caregiver Betsy Arakawa had been found in their Santa Fe, NM, home
-
Bacterial Vaginosis: Treat the Man, Too
In a randomized trial, treatment of the regular male partner with oral and topical agents was strongly associated with a reduced risk of recurrence of bacterial vaginosis in the female partner.
-
Cardiovascular Risk with mRNA COVID Vaccines
A large, nationwide population study in Sweden of the risk of adverse cardiovascular events after messenger ribonucleic acid (mRNA) COVID-19 vaccinations has shown that, except for rare cases of myopericarditis, severe cardiovascular events, such as myocardial infarction, heart failure, and stroke, are reduced, probably because of the prevention of COVID infection.
-
Measles Vaccination in Adults in 2025
The Centers for Disease Control and Prevention has updated measles vaccination recommendations.
-
Infectious Disease Updates
COVID Monoclonals Needed for PrEP; Oral Camostat Ineffective in COVID-19; Mpox: Lessons Learned from Rio
-
Cardiovascular Risk with mRNA COVID Vaccines
A large, nationwide population study in Sweden of the risk of adverse cardiovascular events after messenger ribonucleic acid (mRNA) COVID-19 vaccinations has shown that, except for rare cases of myopericarditis, severe cardiovascular events, such as myocardial infarction, heart failure, and stroke, are reduced, probably because of the prevention of COVID infection.
-
Death Due to the ‘No Name’ Virus in Santa Fe
There is no specific treatment for hantavirus infection and no vaccine. Prevention consists of control and avoidance of rodents and their body fluids and excreta.